​

Edwards Lifesciences (EW) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

EW Stock Forecast

Edwards Lifesciences stock forecast is as follows: an average price target of $75.08 (represents a 5.55% upside from EW’s last price of $71.13) and a rating consensus of 'Buy', based on 21 wall street analysts offering a 1-year stock forecast.

EW Price Target

The average price target for Edwards Lifesciences (EW) is $75.08 based on 1-year price targets from 21 Wall Street analysts in the past 3 months, with a price target range of $81.00 to $68.00. This represents a potential 5.55% upside from EW's last price of $71.13.

EW Analyst Ratings

Buy

According to 21 Wall Street analysts, Edwards Lifesciences's rating consensus is 'Buy'. The analyst rating breakdown for EW stock is 0 'Strong Buy' (0.00%), 13 'Buy' (61.90%), 7 'Hold' (33.33%), 1 'Sell' (4.76%), and 0 'Strong Sell' (0.00%).

Edwards Lifesciences Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jan 08, 2025Lee HambrightBernstein$74.00$74.15-0.20%4.03%
Dec 05, 2024Lee HambrightBernstein$72.00$72.63-0.86%1.22%
Dec 05, 2024Richard NewitterTruist Financial$78.00$72.647.38%9.66%
Dec 05, 2024William PlovanicCanaccord Genuity$68.00$73.25-7.17%-4.40%
Oct 30, 2024David RomanGoldman Sachs$80.00$68.6316.57%12.47%
Oct 30, 2024Travis SteedBank of America Securities$75.00$68.639.28%5.44%
Oct 28, 2024Joanne WuenschCitigroup$81.00$69.0517.31%13.88%
Oct 15, 2024David RescottRobert W. Baird$73.00$69.634.84%2.63%
Oct 11, 2024Patrick WoodMorgan Stanley$70.00$68.262.55%-1.59%
Oct 07, 2024William PlovanicCanaccord Genuity$66.00$65.490.78%-7.21%
Sep 18, 2024Matthew TaylorJefferies$70.00$67.234.12%-1.59%
Sep 13, 2024Richard NewitterTruist Financial$71.00$68.134.21%-0.18%
Sep 09, 2024Matt MiksicBarclays$80.00$66.8119.74%12.47%
Sep 09, 2024Larry BiegelsenWells Fargo$80.00$66.8119.74%12.47%
Jul 31, 2024Narumi NakagiriDaiwa$72.00$63.6413.14%1.22%
Jul 30, 2024Joanna WuenschCitigroup$83.00$63.7430.22%16.69%
Jul 25, 2024Pito ChickeringDeutsche Bank$85.00$60.5840.31%19.50%
Jul 25, 2024Suraj KaliaOppenheimer$90.00$60.5848.56%26.53%
Jul 25, 2024Robbie MarcusJ.P. Morgan$72.00$60.5818.85%1.22%
Jul 25, 2024Shagun SinghRBC Capital$85.00$60.5840.31%19.50%
Jul 25, 2024Rick WiseStifel Nicolaus$70.00$86.95-19.49%-1.59%
Jul 25, 2024Adam MaederPiper Sandler$73.00$86.95-16.04%2.63%
Jul 16, 2024Richard NewitterTruist Financial$110.00$89.5022.91%54.65%
May 30, 2024David RomanGoldman Sachs$107.00$87.0322.95%50.43%
May 14, 2024Pito ChickeringDeutsche Bank$103.00$84.7021.61%44.81%
Apr 15, 2024Shagun SinghRBC Capital$101.00$90.2811.87%41.99%
Apr 11, 2024Anthony PetroneMizuho Securities$105.00$91.5114.74%47.62%
Mar 18, 2024Suraj KaliaOppenheimer$100.00$92.857.70%40.59%
Feb 01, 2023Canaccord Genuity$76.00$78.21-2.83%6.85%
Feb 01, 2023Truist Financial$86.00$76.7012.13%20.91%
Jan 06, 2023Morgan Stanley$95.00$76.3224.48%33.56%
Dec 13, 2022Raymond James$83.00$75.3210.20%16.69%
Dec 12, 2022Citigroup$92.00$75.2522.25%29.34%
Dec 05, 2022Rick WiseStifel Nicolaus$75.00$73.851.56%5.44%
Nov 28, 2022RBC Capital$105.00$75.9838.19%47.62%
Oct 28, 2022Shagun Singh ChadhaRBC Capital$118.00$70.8766.50%65.89%
Jul 30, 2022Richard NewitterTruist Financial$120.00$100.5419.36%68.71%
Apr 27, 2022Canaccord Genuity$137.00$111.5922.77%92.61%
Apr 27, 2022Raymond James$124.00$111.8610.85%74.33%
Apr 27, 2022RBC Capital$135.00$116.2716.11%89.79%
Apr 27, 2022Leerink Partners$138.00$116.2718.69%94.01%
Apr 06, 2022Vijay KumarEvercore ISI$126.00$120.364.69%77.14%
Mar 03, 2022Travis SteedBank of America Securities$130.00$111.9816.09%82.76%
Jan 27, 2022Rick WiseStifel Nicolaus$120.00$101.9617.69%68.71%
Jan 27, 2022Cecilia FurlongMorgan Stanley$136.00$101.9633.39%91.20%
Jan 27, 2022Danielle AntalffyLeerink Partners$130.00$101.9627.50%82.76%
Jan 26, 2022Pito ChickeringDeutsche Bank$113.00$108.634.02%58.86%
Jan 07, 2022Matt MiksicCredit Suisse$140.00$122.3014.47%96.82%
Dec 17, 2021Robbie MarcusJ.P. Morgan$140.00$122.1214.64%96.82%
Dec 09, 2021Larry BiegelsenWells Fargo$133.00$120.3410.52%86.98%
Dec 09, 2021Josh JenningsCowen & Co.$140.00$120.3416.34%96.82%
Dec 09, 2021Suraj KaliaOppenheimer$135.00$120.3412.18%89.79%
Nov 08, 2021Anthony PetroneJefferies$135.00$119.5412.93%89.79%

The latest Edwards Lifesciences stock forecast, released on Jan 08, 2025 by Lee Hambright from Bernstein, set a price target of $74.00, which represents a -0.20% decrease from the stock price at the time of the forecast ($74.15), and a 4.03% increase from EW last price ($71.13).

Edwards Lifesciences Price Target by Period

1M3M12M
# Anlaysts1628
Avg Price Target$74.00$74.50$81.93
Last Closing Price$71.13$71.13$71.13
Upside/Downside4.03%4.74%15.18%

In the current month, the average price target of Edwards Lifesciences stock is $74.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 4.03% increase as opposed to Edwards Lifesciences's last price of $71.13. This month's average price target is down -0.67% compared to last quarter, and down -9.68% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Jan 08, 2025BernsteinMarket PerformMarket PerformHold
Dec 05, 2024BernsteinMarket PerformMarket PerformHold
Dec 05, 2024RBC CapitalOutperformOutperformHold
Dec 05, 2024Canaccord GenuityHoldHoldHold
Dec 05, 2024OppenheimerOutperformOutperformHold
Oct 30, 2024Goldman SachsBuyBuyHold
Oct 30, 2024Bank of America SecuritiesNeutralNeutralHold
Oct 28, 2024Cowen & Co.HoldHoldHold
Oct 28, 2024CitigroupBuyBuyHold
Oct 28, 2024BernsteinPerformUpgrade
Oct 01, 2024UBSUnderperformUnderperformHold
Oct 01, 2024Wells FargoBuyBuyHold
Sep 18, 2024JefferiesHoldDowngrade
Sep 09, 2024BarclaysOverweightOverweightHold
Sep 09, 2024Wells FargoOverweightOverweightHold
Aug 22, 2024CitigroupBuyBuyHold
Jul 31, 2024DaiwaOutperformUpgrade
Jul 25, 2024Canaccord GenuityHoldHoldHold
Jul 25, 2024OppenheimerOutperformOutperformHold
Jul 25, 2024RBC CapitalOutperformOutperformHold
Jul 25, 2024Deutsche BankBuyBuyHold
Jul 25, 2024Cowen & Co.BuyHoldDowngrade
Jul 25, 2024Piper SandlerNeutralNeutralHold
Jul 22, 2024Cowen & Co.BuyBuyHold
Jul 10, 2024CitigroupBuyBuyHold
Jun 06, 2024Cowen & Co.BuyBuyHold
May 30, 2024Goldman SachsBuyInitialise
May 22, 2024CitigroupNeutralBuyUpgrade
May 14, 2024Deutsche BankBuyBuyHold
May 06, 2024BarclaysOverweightOverweightHold
Apr 23, 2024Cowen & Co.BuyBuyHold
Apr 15, 2024RBC CapitalOutperformOutperformHold
Apr 03, 2024CitigroupNeutralNeutralHold
Mar 26, 2024OTR GlobalPositiveUpgrade
Mar 07, 2024Bank of America SecuritiesBuyUpgrade
Feb 07, 2024RBC CapitalOutperformOutperformHold
Feb 02, 2024Wells FargoOverweightUpgrade
Sep 26, 2023Compass PointSellInitialise
Sep 26, 2023OppenheimerOutperformUpgrade
Apr 27, 2023Piper SandlerNeutralNeutralHold
Feb 06, 2023Raymond JamesOutperformMarket PerformDowngrade
Feb 01, 2023CFRABuyUpgrade
Feb 01, 2023Canaccord GenuityHoldHoldHold
Jan 31, 2023Piper SandlerOverweightNeutralDowngrade
Jan 06, 2023Morgan StanleyOverweightOverweightHold
Dec 13, 2022Raymond JamesOutperformOutperformHold
Dec 12, 2022CitigroupBuyBuyHold
Dec 01, 2022Wolfe ResearchPeer PerformDowngrade
Nov 28, 2022RBC CapitalOutperformOutperformHold
Jul 29, 2022Piper SandlerOverweightOverweightHold
Apr 29, 2022CitigroupBuyBuyHold
Apr 27, 2022Canaccord GenuityBuyBuyHold
Apr 27, 2022SVB LeerinkOutperformOutperformHold
Apr 27, 2022Raymond JamesOutperformOutperformHold
Apr 27, 2022RBC CapitalOutperformOutperformHold
Apr 06, 2022Evercore ISIOutperformOutperformHold

Edwards Lifesciences's last stock rating was published by Bernstein on Jan 08, 2025. The company gave EW a "Market Perform" rating, the same as its previous rate.

Edwards Lifesciences Financial Forecast

Edwards Lifesciences Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
Revenue------------$1.53B$1.48B$1.53B$1.46B$1.35B$1.32B$1.37B$1.34B$1.33B$1.31B$1.38B$1.22B$1.19B$1.14B$925.00M$1.13B$1.17B$1.09B
Avg Forecast$1.63B$1.58B$1.59B$1.54B$1.49B$1.45B$1.46B$1.41B$1.36B$1.54B$1.65B$1.57B$1.50B$1.48B$1.51B$1.39B$1.33B$1.33B$1.40B$1.31B$1.35B$1.32B$1.28B$1.16B$1.18B$1.08B$793.92M$1.08B$1.14B$1.04B
High Forecast$1.67B$1.62B$1.63B$1.57B$1.52B$1.49B$1.50B$1.44B$1.38B$1.57B$1.65B$1.57B$1.53B$1.52B$1.54B$1.43B$1.36B$1.33B$1.40B$1.31B$1.35B$1.32B$1.28B$1.16B$1.18B$1.08B$793.92M$1.08B$1.14B$1.04B
Low Forecast$1.59B$1.55B$1.55B$1.50B$1.45B$1.42B$1.43B$1.38B$1.35B$1.52B$1.65B$1.57B$1.47B$1.45B$1.47B$1.36B$1.31B$1.33B$1.40B$1.31B$1.35B$1.32B$1.28B$1.16B$1.18B$1.08B$793.92M$1.08B$1.14B$1.04B
# Analysts97117612614189661222111116101018111321111587655
Surprise %------------1.02%1.00%1.02%1.05%1.01%0.99%0.98%1.02%0.98%0.99%1.07%1.05%1.01%1.06%1.17%1.04%1.03%1.06%

Edwards Lifesciences's average Quarter revenue forecast for Mar 24 based on 6 analysts is $1.57B, with a low forecast of $1.57B, and a high forecast of $1.57B. EW's average Quarter revenue forecast represents a 2.34% increase compared to the company's last Quarter revenue of $1.53B (Dec 23).

Edwards Lifesciences EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts97117612614189661222111116101018111321111587655
EBITDA------------$400.10M$422.80M$569.20M$476.80M$446.60M$506.20M$429.90M$447.20M$409.80M$424.50M$581.30M$421.70M$388.70M$389.90M$-143.70M$389.00M$367.30M$322.00M
Avg Forecast$510.53M$496.22M$497.60M$480.94M$465.59M$454.55M$458.50M$442.77M$425.49M$483.61M$517.70M$540.37M$468.69M$463.45M$471.33M$491.25M$483.56M$439.96M$460.49M$446.59M$446.24M$436.03M$423.10M$358.89M$390.68M$356.38M$261.86M$345.78M$377.63M$341.86M
High Forecast$522.96M$508.30M$509.72M$492.65M$476.93M$465.62M$469.67M$452.12M$431.74M$491.35M$517.93M$648.45M$478.06M$475.11M$482.82M$589.50M$580.28M$439.96M$460.49M$535.91M$446.24M$436.03M$423.10M$430.67M$390.68M$356.38M$261.86M$414.93M$377.63M$341.86M
Low Forecast$497.78M$483.83M$485.18M$468.93M$453.97M$443.20M$447.05M$433.41M$422.36M$475.88M$517.47M$432.30M$459.32M$454.42M$459.57M$393.00M$386.85M$439.96M$460.49M$357.27M$446.24M$436.03M$423.10M$287.11M$390.68M$356.38M$261.86M$276.62M$377.63M$341.86M
Surprise %------------0.85%0.91%1.21%0.97%0.92%1.15%0.93%1.00%0.92%0.97%1.37%1.18%0.99%1.09%-0.55%1.13%0.97%0.94%

6 analysts predict EW's average Quarter EBITDA for Mar 24 to be $540.37M, with a high of $648.45M and a low of $432.30M. This is 35.06% upper than Edwards Lifesciences's previous annual EBITDA (Dec 23) of $400.10M.

Edwards Lifesciences Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts97117612614189661222111116101018111321111587655
Net Income------------$369.90M$384.90M$307.10M$340.50M$398.40M$343.50M$406.40M$373.60M$335.30M$340.10M$489.50M$338.20M$309.50M$325.20M$-121.90M$310.60M$280.20M$274.70M
Avg Forecast$421.41M$406.87M$410.07M$382.56M$371.73M$367.88M$368.73M$351.59M$329.35M$397.49M$415.23M$428.26M$381.19M$354.71M$387.44M$389.33M$395.65M$375.45M$386.98M$353.94M$331.34M$321.85M$335.27M$287.83M$320.35M$267.66M$112.80M$276.09M$299.27M$245.68M
High Forecast$434.75M$419.75M$423.05M$394.67M$383.50M$379.53M$380.41M$375.42M$341.32M$402.10M$415.31M$513.92M$393.11M$366.73M$399.70M$467.20M$474.78M$375.45M$386.98M$424.72M$331.34M$321.85M$335.27M$345.40M$320.35M$267.66M$112.80M$331.31M$299.27M$245.68M
Low Forecast$407.74M$393.67M$396.76M$370.14M$359.67M$355.94M$356.77M$327.75M$323.36M$392.87M$415.15M$342.61M$369.28M$342.69M$374.87M$311.46M$316.52M$375.45M$386.98M$283.15M$331.34M$321.85M$335.27M$230.26M$320.35M$267.66M$112.80M$220.87M$299.27M$245.68M
Surprise %------------0.97%1.09%0.79%0.87%1.01%0.91%1.05%1.06%1.01%1.06%1.46%1.18%0.97%1.21%-1.08%1.13%0.94%1.12%

Edwards Lifesciences's average Quarter net income forecast for Mar 24 is $428.26M, with a range of $342.61M to $513.92M. EW's average Quarter net income forecast represents a 15.78% increase compared to the company's last Quarter net income of $369.90M (Dec 23).

Edwards Lifesciences SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts97117612614189661222111116101018111321111587655
SG&A------------$480.00M$439.60M$468.70M$436.30M$411.00M$377.30M$409.00M$370.30M$424.00M$364.40M$374.50M$330.80M$338.50M$307.20M$274.90M$307.80M$347.20M$306.20M
Avg Forecast$471.61M$458.39M$459.67M$444.28M$430.10M$419.90M$423.55M$409.02M$393.06M$446.75M$478.24M$424.48M$432.97M$428.12M$435.41M$385.89M$500.32M$385.80M$403.81M$350.81M$391.31M$382.35M$371.02M$281.53M$342.59M$312.51M$229.62M$273.60M$331.14M$299.77M
High Forecast$483.10M$469.56M$470.87M$455.10M$440.58M$430.13M$433.87M$417.66M$398.84M$453.90M$478.45M$509.38M$441.63M$438.89M$446.01M$463.07M$600.38M$385.80M$403.81M$420.97M$391.31M$382.35M$371.02M$337.84M$342.59M$312.51M$229.62M$328.32M$331.14M$299.77M
Low Forecast$459.84M$446.95M$448.20M$433.19M$419.37M$409.42M$412.98M$400.38M$390.17M$439.61M$478.03M$339.58M$424.31M$419.79M$424.54M$308.71M$400.26M$385.80M$403.81M$280.65M$391.31M$382.35M$371.02M$225.23M$342.59M$312.51M$229.62M$218.88M$331.14M$299.77M
Surprise %------------1.11%1.03%1.08%1.13%0.82%0.98%1.01%1.06%1.08%0.95%1.01%1.18%0.99%0.98%1.20%1.13%1.05%1.02%

Edwards Lifesciences's average Quarter SG&A projection for Mar 24 is $424.48M, based on 6 Wall Street analysts, with a range of $339.58M to $509.38M. The forecast indicates a -11.57% fall compared to EW last annual SG&A of $480.00M (Dec 23).

Edwards Lifesciences EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts97117612614189661222111116101018111321111587655
EPS------------$0.61$0.63$0.51$0.56$0.65$0.55$0.65$0.60$0.54$0.55$0.79$0.54$0.50$0.52$-0.20$0.50$0.45$0.44
Avg Forecast$0.70$0.68$0.69$0.64$0.62$0.62$0.62$0.59$0.55$0.66$0.69$0.64$0.64$0.59$0.65$0.61$0.62$0.62$0.64$0.57$0.55$0.53$0.55$0.47$0.53$0.44$0.19$0.44$0.50$0.41
High Forecast$0.73$0.70$0.71$0.66$0.64$0.63$0.64$0.63$0.57$0.67$0.69$0.64$0.66$0.61$0.67$0.63$0.63$0.62$0.64$0.57$0.55$0.53$0.55$0.47$0.53$0.44$0.19$0.44$0.50$0.41
Low Forecast$0.68$0.66$0.66$0.62$0.60$0.60$0.60$0.55$0.54$0.66$0.69$0.64$0.62$0.57$0.63$0.59$0.60$0.62$0.64$0.57$0.55$0.53$0.55$0.47$0.53$0.44$0.19$0.44$0.50$0.41
Surprise %------------0.96%1.06%0.79%0.92%1.06%0.89%1.02%1.05%0.98%1.03%1.42%1.14%0.94%1.17%-1.07%1.13%0.90%1.08%

According to 6 Wall Street analysts, Edwards Lifesciences's projected average Quarter EPS for Mar 24 is $0.64, with a low estimate of $0.64 and a high estimate of $0.64. This represents a 5.40% increase compared to EW previous annual EPS of $0.61 (Dec 23).

Edwards Lifesciences Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
TNDMTandem Diabetes Care$36.36$51.7142.22%Buy
DXCMDexCom$86.43$110.0027.27%Buy
ALGNAlign$224.45$252.0012.27%Buy
ZBHZimmer Biomet$111.05$123.0010.76%Hold
SYKStryker$391.07$413.175.65%Buy
EWEdwards Lifesciences$71.13$75.085.55%Buy
MDTMedtronic$91.41$95.184.12%Hold
PODDInsulet$277.11$268.00-3.29%Buy
BSXBoston Scientific$102.71$97.44-5.13%Buy
ABTAbbott Laboratories$127.86$119.10-6.85%Buy

EW Forecast FAQ

Is Edwards Lifesciences a good buy?

Yes, according to 21 Wall Street analysts, Edwards Lifesciences (EW) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 13 'Buy' recommendations, accounting for 61.90% of EW's total ratings.

What is EW's price target?

Edwards Lifesciences (EW) average price target is $75.08 with a range of $68 to $81, implying a 5.55% from its last price of $71.13. The data is based on 21 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Edwards Lifesciences stock go up soon?

According to Wall Street analysts' prediction for EW stock, the company can go up by 5.55% (from the last price of $71.13 to the average price target of $75.08), up by 13.88% based on the highest stock price target, and down by -4.40% based on the lowest stock price target.

Can Edwards Lifesciences stock reach $110?

EW's average twelve months analyst stock price target of $75.08 does not support the claim that Edwards Lifesciences can reach $110 in the near future.

What is Edwards Lifesciences's current price target trend?

1 Wall Street analyst forecast a $74 price target for Edwards Lifesciences (EW) this month, up 4.03% from its last price of $71.13. Compared to the last 3 and 12 months, the average price target increased by 4.74% and increased by 15.18%, respectively.

What are Edwards Lifesciences's analysts' financial forecasts?

Edwards Lifesciences's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $5.82B (high $5.95B, low $5.68B), average EBITDA is $1.82B (high $1.86B, low $1.78B), average net income is $1.46B (high $1.52B, low $1.4B), average SG&A $1.68B (high $1.72B, low $1.64B), and average EPS is $2.44 (high $2.54, low $2.34). EW's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $6.34B (high $6.49B, low $6.18B), average EBITDA is $1.99B (high $2.03B, low $1.94B), average net income is $1.62B (high $1.67B, low $1.57B), average SG&A $1.83B (high $1.88B, low $1.79B), and average EPS is $2.71 (high $2.8, low $2.62).

Did the EW's actual financial results beat the analysts' financial forecasts?

Based on Edwards Lifesciences's last annual report (Dec 2023), the company's revenue was $6B, beating the average analysts forecast of $5.88B by 2.18%. Apple's EBITDA was $1.53B, missing the average prediction of $1.89B by -19.03%. The company's net income was $1.4B, missing the average estimation of $1.51B by -7.29%. Apple's SG&A was $1.82B, beating the average forecast of $1.68B by 8.45%. Lastly, the company's EPS was $2.31, missing the average prediction of $2.49 by -7.10%. In terms of the last quarterly report (Dec 2023), Edwards Lifesciences's revenue was $1.53B, beating the average analysts' forecast of $1.5B by 2.49%. The company's EBITDA was $400.1M, missing the average prediction of $468.69M by -14.63%. Edwards Lifesciences's net income was $369.9M, missing the average estimation of $381.19M by -2.96%. The company's SG&A was $480M, beating the average forecast of $432.97M by 10.86%. Lastly, the company's EPS was $0.61, missing the average prediction of $0.637 by -4.29%